Incidental prostate cancer status in the era post-PSA screening in two tertiary hospitals in Rwanda

Author:

Ndayishimye Theophile1,Mutuyimana Diane Joyeuse2,Ikugabire Sonia2,Ngendahayo Edouard3,Gasana Afrika Guido4,Muhawenimana Emmanuel5,Mwizerwa Jean Luc2

Affiliation:

1. University of Rwanda, urology surgery program

2. college of medicine and health sciences, university of Rwanda

3. King Faisal Hospital

4. Rwanda Military Hospital

5. Centre Hospitalier Universitaire de Kigali

Abstract

Abstract

Introduction : Prostate cancer is the second most common noncutaneous cancer in men, with a lifetime risk of 16%. The incidental discovery of prostate cancer during surgical treatment for benign prostatic hyperplasia (BPH) indicates the significant worldwide occurrence of this disease. This study evaluated the incidence of prostate cancer in specimens of prostate obtained during prostatectomy or trans-urethral resection of the prostate (TURP) for benign diagnoses. Methods Review of all TURP and open prostatectomy specimens obtained for benign pathologies at two tertiary hospitals between January 2015 and October 2022. The preoperative clinical characteristics, pathology reports, and Gleason scores were retrieved for all patients. The primary outcome was the incidence of incidental prostate cancer. Univariable logistic regressions were performed to assess associations between prostate-specific antigen (PSA) levels, preoperative clinical characteristics of patients, and primary . Results The study included 153 patients ranging in age from 47 to 97 years whose procedures were performed for benign diagnoses. Prostate cancer was diagnosed in six individuals (6/153) (4%). The Gleason score varied, ranging from 3 + 3 = 6 to 4 + 5 = 9. The patients' disease stages included pT1a, pT1b, pT1c, and T3N1M0. Active surveillance was chosen for three of the patients, while the remaining three underwent androgen deprivation therapy (ADT). Preoperative hematuria and low back pain were found to be independent predictors of incidental prostate cancer. All incidental prostate cancers were found in patients with PSA levels higher than 4 ng/mL. Conclusion There is a low rate of incidental prostate cancer among surgical specimens from patients treated for BPH, and core needle biopsies can be omitted for patients with a PSA lower than 4 ng/ml and without clinical signs suggestive of metastasis or invasion like, such as low back pain and hematuria. In addition to a low rate, only one-third of diagnosed patients required actual treatment. Prospective and more extensive studies are recommended to guide systematic histopathological review of surgical specimens from patients with BPH.

Publisher

Springer Science and Business Media LLC

Reference25 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021

2. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418–9.

3. Cancer progress and priorities: Prostate cancer;Kensler KH;Cancer Epidemiol Biomarkers Prev,2020

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018

5. National Cancer Institute;Heller JR;JAMA,1951

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3